10x Genomics, Inc. (TXG) |
| 43.74 -0.735 (-1.65%) 07-17 16:00 |
| Open: | 42.845 |
| High: | 44.48 |
| Low: | 42.75 |
| Volume: | 2,567,096 |
| Market Cap: | 5,553(M) |
| PE Ratio: | -257.29 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Healthcare Information Services |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 54.10 |
| Resistance 1: | 46.32 |
| Pivot price: | 40.86 |
| Support 1: | 35.00 |
| Support 2: | 28.01 |
| 52w High: | 46.32 |
| 52w Low: | 11.16 |
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
| EPS | -0.170 |
| Book Value | 6.240 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.808 |
| Profit Margin (%) | -3.55 |
| Operating Margin (%) | -11.30 |
| Return on Assets (ttm) | -4.5 |
| Return on Equity (ttm) | -3.0 |
Sat, 18 Jul 2026
Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (TXG), Elevance Health (ELV) and Johnson & Johnson (JNJ) - The Globe and Mail
Wed, 15 Jul 2026
10x Genomics sets Aug. 6 webcast to discuss second-quarter results - Stock Titan
Wed, 15 Jul 2026
Top 3 Health Care Stocks That May Implode This Month - Benzinga
Wed, 15 Jul 2026
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026 - Sahm
Tue, 14 Jul 2026
TXG Stock Rallies As Wall Street Hikes Price Targets - StocksToTrade
Mon, 13 Jul 2026
10x Genomics, Inc. Stock 12‑Month Price Target Raised to $35.46, Implies 17% Downside - TradingView
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |